What Are dMMR and MSI-H? What Do They Mean in Pathology, and How Do They Change Cancer Treatment?
In this article
What Does It Mean if Your Report Says dMMR or MSI-H?
These terms are crucial biological fingerprints that reveal not only the tumor’s name, but also its character, weaknesses and relationship with the immune system . They are a compass that guides your treatment course.
1. Biological Mechanism: The Body’s “Spell Check”
To understand the relationship between cancer and these terms, we need to look inside the cell’s workshop. Our cells divide continuously, copying a DNA library of 3 billion letters with every division.
During this enormous copying process, just as a fast typist may hit the wrong key, “letter errors” (mutations) occur. In a healthy body, these errors are immediately detected and repaired by a “Spell-Checking Team” (Repair Proteins: MLH1, MSH2, MSH6, PMS2).
The terms in your report refer to a malfunction at precisely this point.
dMMR (Cause)
Defective Mismatch Repair: The repair team (proteins) is missing or not working. There is no repair crew.
MSI-H (Consequence)
Microsatellite Instability-High: Thousands of errors accumulate in DNA because the repair crew is absent. The DNA is unstable.
2. What Might You See in Your Report? (Testing Methods)
A. Immunohistochemistry (IHC)
The pathologist performs this test by staining tumor tissue with special dyes and examining it under a microscope.
-
What Is Examined? The 4 main repair proteins (MLH1, MSH2, MSH6, PMS2).
-
Normal Result (MMR-Proficient / pMMR): If the cell nuclei stain brown, the proteins are present and working. The report says “Nuclear expression preserved.”
-
Abnormal Result (dMMR): If staining is absent, that protein is missing. The report states “Loss of nuclear expression observed” (Loss of nuclear expression). This indicates that the repair system is defective (dMMR).
B. PCR or Genetic Testing
This test uses DNA analysis equipment rather than a microscope.
-
What Is Examined? The length of short, repetitive DNA sequences called “microsatellites.”
-
Normal Result (MSS - Stable): The length of the repetitive sequences is stable and unchanged.
-
Abnormal Result (MSI-H - High Instability): Because the repair mechanism is not working, these sequences have become longer or shorter (a shift has occurred). Generally, if 2 or more of 5 markers show a shift, MSI-H is diagnosed.
3. How Does This Result Change Treatment?
The “Targeted Therapy” and Immunotherapy Revolution
MSI-H tumors look very “conspicuous” to the immune system because they carry thousands of errors. However, the tumor applies a “brake” mechanism (PD-L1) to protect itself.
Immunotherapy drugs (e.g., Pembrolizumab, Nivolumab) release this brake. When the mask falls, the immune system attacks the tumor fiercely. These patients have a high chance of complete recovery even in advanced disease.
Avoiding Unnecessary Chemotherapy
This is particularly vital information for Stage II Colon Cancer patients. MSI-H tumors do not take the damage caused by standard chemotherapy (5-FU) seriously.
Chemotherapy may therefore provide no benefit in stage II MSI-H patients and may even be harmful. Your doctor can use this test to spare you unnecessary chemotherapy.
4. Inherited or Acquired? (Lynch Syndrome)
A dMMR finding in your report suggests that this may be an inherited condition (Lynch Syndrome). However, not every dMMR case is inherited.
-
🧬Lynch Syndrome (3-5%): The person inherited the defective gene from their mother or father. Risk increases not only for bowel cancer, but also for uterine, ovarian and gastric cancers. Family screening is needed.
-
⏳Sporadic (10-15%): Not inherited. Develops with aging. To distinguish the two, your doctor may request a BRAF V600E test. If BRAF is positive, the condition is generally not inherited (good news).
Frequently Asked Questions
My report says “MSS.” Is that bad?
No. This is the case in 85% of cancers. It indicates that your DNA repair system is intact. Standard treatments still apply to you. It simply means you are not the first candidate for “dMMR-specific” immunotherapy.
Do I need surgery again for the test?
Usually not. These tests (IHC or PCR) can easily be performed on the existing biopsy or surgical specimen stored in the pathology laboratory.
Which cancers are tested?
With FDA approval, it is now a “Tumor-Agnostic” marker. It is most common in colon, uterine (endometrial) and gastric cancers, but can be tested in any cancer type (breast, prostate, etc.).
Is immunotherapy a guaranteed solution?
There are no guarantees in medicine, but immunotherapy response rates in MSI-H patients are quite high, at 40-60%. The chance of a “complete response” (disappearance of the cancer) is much greater than in other types.
A Compass for Your Treatment Course
Having dMMR or MSI-H in your report is one of the greatest opportunities modern medicine can offer you. It is a clue that tells us not just the name of the disease, but how it might be defeated. If you see these terms in your report, be sure to discuss Immunotherapy and Genetic Counseling options with your oncologist.
- Le, D. T., et al. (2015): "PD-1 Blockade in Tumors with Mismatch-Repair Deficiency." (NEJM).
- André, T., et al. (2020): "Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer (KEYNOTE-177)." (NEJM).
- NCCN Guidelines (2024): "Genetic/Familial High-Risk Assessment: Colorectal" and "Colon Cancer Guidelines".
- Dudley, J. C., et al. (2016): "Microsatellite Instability in Cancer: Challenges and Opportunities." (Cancer Cell).
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.